濮阳东方医院男科电话(濮阳东方看妇科口碑好收费低) (今日更新中)

Former Gov. Deval Patrick has decided not to run for president and plans to announce his decision soon, a source close to the Massachusetts Democrat tells CNN.Patrick, a two-term governor and close ally to former President Barack Obama, had been considering a 2020 run after entering the private sector and taking a job at Bain Capital in 2015. He had upped his political involvement ahead of the 2018 midterms -- endorsing candidates in South Carolina, Texas, New Jersey and a handful of other states -- leading many to believe he was going to jump into the race.Patrick, despite the speculation that he was going to run, had repeatedly acknowledged the enormity of the decision."It's on my radar screen," Patrick told a public radio station in Kansas City during the midterms, adding that "it's a huge decision.""I am trying to think through 2020," Patrick said. "And that's a decision I'm trying to think through from a personal and family point of view."Patrick also expressed concerns about standing out in what is expected to be a wide-open Democratic field."It's hard to see how you even get noticed in such a big, broad field without being shrill, sensational or a celebrity," Patrick told David Axelrod, a former top Obama adviser, in September. "And I'm none of those things and I'm never going to be any of those things."A spokesman for Patrick declined to comment on the governor's decision not to run for President, which was first reported by Politico.Patrick has been receiving private support from many of the same aides and advisers who helped Obama vault into the White House in 2008."Deval would make an outstanding President," Valerie Jarrett, Obama's former senior adviser, told the New Yorker in November. "President Obama and Deval are very much alike in terms of their core values, what drove them into public service, their willingness to lend a hand, the responsibility to give back." 1918

Feel like taking a late night swim in your backyard pool? Finding a giant gator beat you to it is not want you want to see.A homeowner in Sarasota, Florida got the surprise of a lifetime when an 11-foot gator was discovered taking a late Friday night dip on the lanai.Sarasota County sheriff's deputies and a gator trapper were contacted to remove the gator.The gator didn't immediately want to go.After a short struggle, the gator gave up and was taken away quietly.  481

For the first time, the FDA has authorized coronavirus tests that can be sold directly to Americans who do not have to go through a health care provider.An emergency use authorization is not a full approval from the FDA, but allows the tests to be used in a non-clinical or non-hospital setting.The LabCorp’s Pixel COVID-19 Test Home Collection Kit can be used by any adult age 18 or over. The test kit allows individuals to take a nasal swab at home and send the sample to LabCorp for testing.Those who test positive will receive a call from a health care provider. Negative tests are delivered via an online portal or through email.The FDA says that the tests can be purchased online or in stores, and can help people determine whether they need to quarantine.“This is the first kit for consumers to self-collect a nasal sample for COVID-19 in their home that does not require a prescription,” said Jeff Shuren, M.D., J.D., director of FDA’s Center for Devices and Radiological Health. “While many home collection kits can be prescribed with a simple online questionnaire, this newly authorized direct-to-consumer collection kit removes that step from the process, allowing anyone to collect their sample and send it to the lab for processing.”The company says the out of pocket cost is 9 for those who do not have the test covered by insurance. The tests take one to two days to process, once received via FedEx.“With the first over-the-counter at-home collection kit ever authorized by the FDA for COVID-19, we are empowering people to learn about their health and make confident decisions,” said Dr. Brian Caveney, chief medical officer and president of LabCorp Diagnostics . “With this authorization, we can help more people get tested, reduce the spread of the virus and improve the health of our communities.” 1828

For each step on his morning run, Rodney Everett takes a deep breath. The air in his lungs is fresh for the first time in 50 years."You come out in the morning and see the sky is yellow, and you smell this smell," said Everett.The smell came from the largest oil refinery on the east coast, Philadelphia Energy Solutions. The refinery sat a few blocks from Everett’s South Philadelphia neighborhood. 408

FOSTER CITY, Calif. – The maker of remdesivir, a drug shown to shorten recovery time for severely ill COVID-19 patients, has released its pricing for the treatment.Gilead announced Monday that it will charge ,340 for a typical treatment course for people covered by government health programs in the United States and other “developed countries.”As for Americans with private insurance, they’ll be charged ,120, “because of the way the U.S. system is set up and the discounts that government healthcare programs expect,” Gilead said.Based on current treatment patterns, Gilead said the vast majority of patients are expected to receive a five-day treatment course using six vials of remdesivir. Individually, each vial will cost 0 for those covered by a government insurer, and 0 per vile for those with a private insurer.In poorer countries, with less health care resources, generic drugmakes will be allowed to make the drug and sell it for far less than in the U.S.The pricing has already come under fire, because the development of the drug was largely funded by taxpayer money.Gilead’s CEO, Daniel O’Day, wrote in an open letter that the company approached its pricing decision with the aim of helping as many patients as possible, as quickly as possible.“At the level we have priced remdesivir and with government programs in place, along with additional Gilead assistance as needed, we believe all patients will have access,” wrote O’Day.O’Day said Gilead has entered into an agreement with the U.S. Department of Health and Human Services (HHS) whereby HHS and states will continue to manage allocation to hospitals until the end of September. After this period, once supplies are less constrained, HHS will no longer manage allocation.The U.S. Food and Drug Administration (FDA) has actually not yet approved remdesivir for any use, but it has granted an Emergency Use Authorization (EUA) for the treatment of hospitalized patients with severe COVID-19.This treatment is much different than COVID-19 vaccines, which are still in development. Public health leader Dr. Anthony Fauci has said that the U.S. should have a "couple hundred million" doses of a coronavirus vaccine by the beginning of 2021. 2226

来源：资阳报